Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
30.09. | Nxera Pharma Announces Second Milestone In AbbVie Neurology Collaboration, Secures $10 Mln Payment | 366 | AFX News | TOKYO (dpa-AFX) - Nxera Pharma Co., Ltd. (SOLTF, 4565.T) announced it has reached a second milestone in its multi-target discovery collaboration with AbbVie focused on neurological diseases.... ► Artikel lesen | |
30.09. | Nxera Pharma to Receive US$10 Million Milestone Payment from AbbVie under Collaboration Targeting Neurological Diseases | 122 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge and London, UK, 30 September 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) announces that it has reached a second important R&D milestone under its... ► Artikel lesen | |
18.09. | Singtel's Nxera secures $643m green loan for DC Tuas data centre | 6 | Singapore Business Review | ||
17.09. | Nxera Pharma and Cancer Research UK Announce First Patient Dosed in Phase 2a Trial of Investigational Cancer Immunotherapy HTL0039732 | 147 | GlobeNewswire (Europe) | HTL0039732 (also known as NXE0039732) is Nxera's novel oral EP4 antagonist being investigated to treat a wide range of solid cancers in combination with other immunotherapiesCancer Research UK's Centre... ► Artikel lesen | |
08.08. | Nxera Pharma reports Q2 results | 1 | Seeking Alpha | ||
08.08. | Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half 2025 | 160 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 8 August 2025 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the second... ► Artikel lesen | |
06.08. | Nxera debuts an obesity pipeline; BridgeBio battles Alynam for market share | 18 | BioPharma Dive | ||
06.08. | Nxera Pharma: Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management | 178 | GlobeNewswire (Europe) | Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscapeDesigned... ► Artikel lesen | |
NXERA PHARMA Aktie jetzt für 0€ handeln | |||||
29.07. | Singtel's Data Centre Arm Nxera Embarks on Ambitious Hiring Plan for AI Skills | 1 | The Fast Mode | ||
04.07. | Nxera Pharma To Receive $4.8 Mln Milestone As Centessa Advances ORX142 To Phase 1 Study | 2 | RTTNews | ||
04.07. | Nxera Pharma to Receive US$4.8 Million in Milestone Payments Following Centessa's Initiation of Clinical Development of ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist | 243 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 4 July 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that it will receive US$4.8 million in milestone payments from Centessa Pharmaceuticals... ► Artikel lesen | |
03.06. | Nxera Hits Important Milestone in Diabetes Drug Partnership with Eli Lilly | 9 | Insider Monkey | ||
03.06. | Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568 | 202 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 3 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that its partner, Neurocrine Biosciences ("Neurocrine") has dosed the first... ► Artikel lesen | |
02.06. | Nxera Pharma Reaches Key Milestone In Lilly Partnership For Diabetes & Metabolic Disease Research | 591 | AFX News | INDIANAPOLIS (dpa-AFX) - Nxera Pharma Co., Ltd. announced that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Co. (LLY)... ► Artikel lesen | |
02.06. | Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases | 270 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 2 June 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration... ► Artikel lesen | |
02.05. | Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025 | 227 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 2 May 2025 - Nxera Pharma ("the Company" or "Nxera"; TSE: 4565) provides an update on operational activities and reports its consolidated results for the first quarter... ► Artikel lesen | |
01.05. | Nxera Pharma's Partner Neurocrine Biosciences Initiates Phase 3 Registrational Program of NBI-1117568 as a Potential Treatment for Adults with Schizophrenia | 263 | GlobeNewswire (Europe) | NBI-1117568 is an oral, muscarinic M4 selective receptor agonist discovered by Nxera advancing through clinical development under a multi-program collaboration with NeurocrineFor more information... ► Artikel lesen | |
01.05. | Nxera Pharma Appoints Top-Ranked Biopharma Investment Analyst Shinya Tsuzuki as Head of Investor Relations | 1 | GlobeNewswire (USA) | ||
25.03. | Nxera Pharma's Partner Tempero Bio Initiates Phase 2 Trial with TMP-301 for Alcohol Use Disorder | 338 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 25 March 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) announces that its partner Tempero Bio, Inc. has initiated a Phase 2 trial of TMP-301, a... ► Artikel lesen | |
14.02. | Nxera Pharma Operational Highlights and Consolidated Results for the Fourth Quarter and Full Year 2024 | 453 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 14 February 2025 - Nxera Pharma Co., Ltd. ("Nxera" or "the Company"; TSE 4565) provides an update on operational activities and reports its consolidated results for... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
PFIZER | 20,735 | -1,03 % | Pharmaindustrie: Darum birgt der Pfizer-Deal Risiken | Die US-Regierung hat mit dem Pharmakonzern Pfizer Inc. eine Vereinbarung zur Senkung der Medikamentenpreise erzielt, die an der Börse für Erleichterung sorgte. Im Gegenzug für die Zusage, US-Preise... ► Artikel lesen | |
NOVARTIS | 111,58 | +0,18 % | Aktien Europa: Massive Gewinne der Luxuswerte beflügeln Kurse | AMSTERDAM/LONDON/PARIS/ZÜRICH (dpa-AFX) - Europas Aktienmärkte haben am Mittwoch zugelegt. Deutliche Gewinne der Luxuswerte, allen voran des Schwergewichts LVMH, trieben die Kurse. Der EuroStoxx... ► Artikel lesen | |
GILEAD SCIENCES | 100,88 | -0,71 % | Gilead-Partner Tubulis: Rekord-Finanzierung für deutsche Biotech-Hoffnung | Das Biotechnologie-Unternehmen Tubulis, welches sich auf die Entwicklung sogenannter Antikörper-Wirkstoff-Konjugate (ADCs) gegen Krebs fokussiert, hat bei neuen und bestehenden Investoren frisches Kapital... ► Artikel lesen | |
SANOFI | 85,47 | +1,50 % | JPMORGAN stuft SANOFI auf 'Overweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Sanofi auf "Overweight" mit einem Kursziel von 105 Euro belassen. Für das dritte Quartal liegt Analyst Richard Vosser beim Gewinn... ► Artikel lesen | |
ABBVIE | 194,20 | -0,10 % | Dividendenbekanntmachungen (15.10.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,59 USD 0,5082 EUR ABBVIE INC US00287Y1091 1,64 USD 1,4127 EUR ABBVIE INC CDR CA00288K1084 0... ► Artikel lesen | |
ROCHE | 306,85 | +0,72 % | Roche Holding: Aktie geht steil! | ||
ABBOTT LABORATORIES | 108,80 | -2,18 % | Analyst See Noise In Q3 P&L, Affirms Abbott's Medtech Strength | ||
HAEMATO | 10,900 | 0,00 % | EQS-Adhoc: M1 Kliniken AG: HAEMATO AG veräußert 100 %-Tochtergesellschaft HAEMATO Pharm GmbH an PHOENIX group | EQS-Ad-hoc: M1 Kliniken AG / Schlagwort(e): Verkauf/Beteiligung/Unternehmensbeteiligung
M1 Kliniken AG: HAEMATO AG veräußert 100 %-Tochtergesellschaft HAEMATO Pharm GmbH an PHOENIX group
16.10.2025... ► Artikel lesen | |
INCYTE | 75,44 | -0,37 % | Incyte wird Daten zum bispezifischen TGFßR2×PD-1-Antikörper und zum KRAS-G12D-Inhibitor auf dem Kongress der European Society of Medical Oncology (ESMO) 2025 präsentieren | Incyte (Nasdaq:INCY) kündigte heute an, dass Ergebnisse aus Proof-of-Concept-Studien der Phase 1 zu INCA33890, einem vielversprechenden TGFßR2×PD-1-gerichteten bispezifischen Antikörper, und INCB161734... ► Artikel lesen | |
EDWARDS LIFESCIENCES | 62,22 | -0,67 % | Edwards Lifesciences Corporation: Updated ESC/EACTS Guidelines Mark Advancement in Structural Heart Disease Care | Edwards Lifesciences (NYSE: EW) welcomes the updated ESC/EACTS guidelines for valvular heart disease, which establish a simplified care pathway for all severe aortic stenosis (AS) patients, regardless... ► Artikel lesen | |
WPD PHARMACEUTICALS | 0,002 | 0,00 % | WPD Pharmaceuticals Inc (2): WPD Pharmaceuticals suspended by CSE | ||
HALEON | 3,985 | +1,84 % | Haleon plc - 6-K, Report of foreign issuer | ||
BIONANO GENOMICS | 1,995 | -5,45 % | Bionano Genomics: Effizienz vor Expansion - CEO skizziert neue Strategie | ||
TONIX PHARMACEUTICALS | 17,400 | +3,57 % | XFRA NEW INSTRUMENTS AVAILABLE ON 14.10.2025 | The following instruments on XETRA do have their first trading 14.10.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 14.10.2025
Aktien
1 CA19260V1067 Coinbase Global Inc.
2... ► Artikel lesen | |
GRIFOLS | 11,755 | -1,88 % | EQS-News: Biotest AG: Einberufung einer außerordentlichen Hauptversammlung auf Verlangen der Grifols S.A. | EQS-News: Biotest AG
/ Schlagwort(e): Hauptversammlung
Biotest AG: Einberufung einer außerordentlichen Hauptversammlung auf Verlangen der Grifols S.A.
19.09.2025... ► Artikel lesen |